Skip to main content
Journal of Nephropathology logoLink to Journal of Nephropathology
. 2013 Apr 1;2(2):98–103. doi: 10.12860/JNP.2013.16

IgM nephropathy; can we still ignore it

Aruna Vanikar 1,*
PMCID: PMC3891147  PMID: 24475434

Abstract

Context:IgM nephropathy (IgMN) is a relatively less recognized clinico-immunopathological entity in the domain of glomerulonephritis , often thought to be a bridge between minimal change disease and focal segmental glomerulosclerosis.

Evidence Acquisitions: Directory of Open Access Journals (DOAJ), Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science has been searched.

Results: IgM nephropathy can present as nephritic syndrome or less commonly with subnephrotic proteinuria or rarely hematuria. About 30% patients respond to steroids whereas others are steroid dependent / resistant. They should be given a trial of Rituximab or stem cell therapy.

Conclusions:IgM nephropathy (IgMN) is an important and rather neglected pathology responsible for renal morbidity in children and adults in developing countries as compared to developed nations with incidence of 2-18.5% of native biopsies. Abnormal T-cell function with hyperfunctioning suppressor T-cells are believed to be responsible for this disease entity. Approximately one third of the patients are steroid responders where as the remaining two thirds are steroid resistant or dependent. Therapeutic trials including cell therapies targeting suppressor T-cells are required.

Keywords: IgM nephropathy, Minimal change disease, Focal segmental glomerulosclerosis, Hypertension, Proteinuria

1. Context

IgM nephropathy (IgMN) is a relatively less recognized clinico-immunopathological entity in the domain of glomerulonephritis (GN), often thought to be a bridge between minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).

2. Evidence Acquisition

Directory of Open Access Journals (DOAJ) Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science were searched with key words relevant to IgM nephropathy, proteinuria, minimal change disease, focal segmental glomerulosclerosis and hypertension .

3. Results

IgM nephropathy was first described independently by two groups; Cohen and Border et al, and Bhasin et al, in 1978 (1-2). Their series of native renal biopsies displayed mesangial hypercellularity on light microscopy, diffuse granular mesangial IgM and C3 deposits on immunofluorescence (IF), and on electron microscopy (EM) generalized foot process effacement with mesangial electron dense deposits in about 50% of the patients. Early avalanche of these reports from Finland, US, UK and other developed countries receded only to be taken up by developing countries. Since then many papers related to IgMN from developing and occasionally developed nations are being published every year.

3.1. Epidemiology

Most of the studies have reported on prevalence of IgMN as frequency/ percentage of renal biopsies with diagnosis of IgMN reported from 2 % to 18.5 % in native biopsies (3-13). Occasional cases of IgMN in transplant biopsies have also been reported (14). The etiology of IgMN like IgA nephropathy/C1q nephropathy is largely unknown. However common denominator in all these studies is exclusion of systemic diseases like lupus nephritis, rheumatoid arthritis, diabetes and diabetic nephropathy, Alport’s syndrome and paraproteinemias.

3.2. Pathogenesis

The pathogenesis of this disease entity still remains elusive. Classical immune complex mediated activation of complement system leading to mesangial injury and reaction has been observed. Majority of the cases show associated presence of C1q and C4 deposits along with IgM in glomerular mesangium whereas properdin and factor B are conspicuous by there absence (6,15,16). C3 deposits are more common accompaniments rather than C1q deposits in these biopsies. Thus classical complement path way appears to play a major role in the evolution of this disease. The source of antigens triggering immune complex formation is still unknown, but it is hypothesized that certain antigens in the environment (or food) which preferentially elicit IgM responses may be responsible for the genesis of this disease (11,17-20). Abnormalities of T-lymphocyte function with stimulation of cytotoxic T-cells and down-regulation of natural suppressor/ regulatory T-cells may be an integral factor in the causation of this disease and inability for clearance of immune complexes by mesangial cells (15,21). Reports on increased serum IgM/ IgM-immune complex concentration in patients with IgMN are available in literature (16,17). However there are no studies reporting on abnormalities of IgM molecule in these patients.

3.3. Pathology

3.3.1. Light microscopy:

Light microscopy and IF are mandatory for diagnosis of IgMN. The spectrum of morphological changes in glomerular pathology range from mild to moderate mesangial proliferation in majority of the cases involving about 70-75%, followed by FSGS in 15-20% and unremarkable morphology/ MCD in 5-10% biopsies (11,20-25). (figure 1a). Tubular and interstitial injuries are manifested as secondary pathology associated with primary glomerular pathology. Tubular and interstitial injury including chronic changes in the form of tubular atrophy and interstitial fibrosis correspond with progression in glomerular lesion however fibrointimal proliferation of vessel wall is not significant in these biopsies (26-30). A comparison of some studies from different geographical regions is presented in the table 1.

Figure1 (a).

Figure1 (a)

Photomicrograph showing glomerulus with mild mesangial prominence, (H & E stain, x 400)

Table 1 . Histopathology findings of IgM nephropathy in different geographical regions and age groups .

Study Total patients Unremarkable/MCD (%) MePGN (%) FSGS (%) Others (%) Steroid response (%)
O’Donoghue et al, 1991 54 0(0) 47 (87) 6 (11.1) Crescentic GN-1(1.9) 5 out of 18 responded
Zeis PS et al 2001 64 20 (31.3) 37 (57.8) 7 (10.9) Nil 14(21.9)-Responders,
50(78.1)-Resistant
Myllymäki et al, 2003 110 38 (34.5) 33 (30.0) 39 (35.5) Nil 47(42.7)-Responders,
50(45.5)-Dependent,
13(11.8)-Resistant
Singhai et al, 2011 117 11 (9.4) 87 (74.4) 19 (16.2) Nil 42(40.2)- Responders,
75(59.8)- Resistant/ dependent
Vanikar et al, 2011 28 8 (28.6) 17 (60.7) 3 (10.7) Nil 7(25.0)-Responders,
21(75.0)-Dependent/resistant

Key to table 1.MCD: Minimal change disease, ESRD: End stage renal disease, GN: Glomerulonephritis, MePGN: Mesangial proliferative glomerulonephritis, FSGS: Focal and segmental glomerulosclerosis

3.3.2. IF findings

IgM deposits with intensity of ≥ 2+ in more than 50% mesangial regions of non-sclerotic glomeruli are predominant features. The associated immune deposits are C3 in 15-20% followed by IgG and IgA. These immune complexes may also be noted across capillary membranes. The intensity of other immune deposits is usually less than that of IgM deposits (figure 1b) (20-31).

Figure1 (b).

Figure1 (b)

Immunofluorescence study showing glomerulus with IgM deposits in mesangial regions and capillaries (3 + to 4 +), anti-human IgM antiserum, x 400

3.3.3. Electron microscopy (EM)

Few reports on EM findings in these biopsies have shown small, granular electron dense deposits in mesangium and para-mesangium accompanied by mesangial hypercellularity and widening of mesangial regions, variable degrees of foot process effacement correlating with extent of proteinuria have also been observed. The deposits are typically of low volume and density (7,8).

3.4. Clinical presentation

IgMN presents in the age group of 13 to 78 years in adults and adolescents, and in the age group of 2 to 12 years in children. In children the common age of presentation is about 6 years whereas in adults it is usually in late thirties to late fifties. Some studies have reported male predilection and others have reported female predilection. However it has been noted that males are more commonly affected than females when the presentation is nephritic syndrome (NS), whereas females usually present with hematuria or sub-nephrotic proteinuria. Hypertension is roughly noted in up to 30% of the patients (8,11,20,23,32-33) (table 2).

Table 2 . Clinical presentation of IgM nephropathy in different geographical regions and age groups .

Study Total patients Males: Females Mean Age in years (range) Presentation Hypertension (%) Mean Serum creatinine (mg/dL)
O’Donoghue et al, 1991 54 35:19
(64.8:35.2)
31
(14-69)
NS-31 (57.4),
PU-19 (35.2),
HU-4 (7.4)
15 (27.8) 1.07 (median)
Chan YH et al, 2000 39 28:11
(71.8:28.2)
35 ±2 NS-18(46.2),
PU-11(28.2),
PHU-9 (23.1),
HU- 1 (2.5)
7 (17.9) 1.14 (median)
Zeis PS et al 2001 64 33:31
(51.6:48.4)
2-14 NS-20 (31.2),
PU-14 (21.9),
HU-18 (28.1),
PHU-12 (18.8)
3 (4.7) Not mentioned
Myllymäki et al, 2003 110:
36-children
74-adults
63:47
(57.3: 42.7)
6 (1-15)
29
(17-75)
NS-50 (45.5),
others-60 (54.5)
55 (50) Not mentioned
Singhai et al, 117 62: 55
(53: 47)
29
(13-78)
NS (100) 12 (10.3) 1.46 ±1.6
Vanikar et al, 2011 28 24:4
(85.7: 14.3)
10
(2-12)
NS (100) 2 (7.1) 0.7 ±0.3

Key to table 2. NS- Nephrotic syndrome, HU: Hematuria, PU: Proteinuria, PHU: Proteinuria and hematuria

4. Treatment modalities

Corticosteroids remain the mainstay of therapeutic strategies in these patients. Unfortunately only one third of the patients, mainly with MCD/unremarkable glomerular morphology respond to steroids. Calcineurin inhibitors and Rituximab have been tried in limited studies and have shown favorable short term response (8,11,31-35). However therapeutic strategies targeting suppressor T-cells and cell therapies should be tried in these patients.

4.1. Prognostic indicators

Women with hematuria have been found to have better prognosis than all other patients. Hypertension and proteinuria are poor prognosticators whereas age has no role in prognosis. In the largest reported series of 110 patients with 15 years follow-up, Myllymäki et al state that clinically hypertension and steroid resistance are bad prognosticators (8). Steroid resistant cases were found to have FSGS on re-biopsy. In histological criteria, interstitial fibrosis was the most important marker for poor prognosis. FSGS lesions have worst prognosis with high probability of progression to end stage renal disease within 5 years as compared to FSGS without IgM deposits (8,11,20,35). Similarly MCD with IgM deposits has worse prognosis than MCD without IgM deposits (11,20,35).

5. Conclusions

IgMN is an important and rather neglected pathology responsible for renal morbidity in children and adults in developing countries as compared to developed nations with incidence of 2-18.5% of native biopsies. Abnormal T-cell function with hyperfunctioning suppressor T-cells are believed to be responsible for this disease entity. Approximately one third of the patients are steroid responders where as the remaining two thirds are steroid resistant or dependent. Therapeutic trials including cell therapies targeting suppressor T-cells are required.

Conflicts of interest

I declare that I have no conflict of interest regarding this article.

Funding/Support

No funding from any source.

Implication for health policy/practice/research/medical education:

IgM nephropathy (IgMN) is an important and rather neglected pathology responsible for renal morbidity in children and adults in developing countries as compared to developed nations with incidence of 2-18.5% of native biopsies. Abnormal T-cell function with hyperfunctioning suppressor T-cells are believed to be responsible for this disease entity. Approximately one third of the patients are steroid responders where as the remaining two thirds are steroid resistant or dependent. Therapeutic trials including cell therapies targeting suppressor T-cells are required.

Please cite this paper as:VanikarA.IgM nephropathy; can we still ignore it. J Nephropathology. 2013; 2(2): 98-103. DOI: 10.5812/nephropathol.9872

References

  • 1.Cohen AH, Border WA, Glassock RJ. Nephrotic syndrome with glomerular mesangialIgM deposits. Lab Invest. 1978;38:610. [PubMed] [Google Scholar]
  • 2.Bhasin HK, Abeulo JG, Nayak R, Esparza AR. Mesangial proliferative glomerulonephritis. Lab Invest. 1978;39 (1):21–9. [PubMed] [Google Scholar]
  • 3.Kishimoto H, Arakawa M. Clinico-pathological characterization of mesangial proliferative glomerulonephritis with predominant deposition of IgM. Clin Exp Nephrol. 1999;3 (2):110–5. [Google Scholar]
  • 4.Kopolovic J, Shvil Y, Pomeranz A, Ron N, Rubinger D, Oren R. IgM nephropathy: morphological study related to clinical findings. Am J Nephrol. 1987;7(4):275–80. doi: 10.1159/000167485. [DOI] [PubMed] [Google Scholar]
  • 5.Lawler W, Williams G, Tarpey P, Mallick NP. IgM associated primary diffuse mesangial proliferative glomerulonephritis. J Clin Pathol. 1980;33 (11):1029–38. doi: 10.1136/jcp.33.11.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mampaso F, Gonzalo A, Teruel J, Losada M, Gallego N, Ortuno J. et al. Mesangial deposits of IgM in patients with the nephrotic syndrome. Clin Nephrol. 1981;16 (5):230–4. [PubMed] [Google Scholar]
  • 7.Mubarak M, Kazi JI, Malik S, Lanewala A, Hashmi S. Clinicopathologic characteristics and steroid response of IgM nephropathy in children presenting with idiopathic nephrotic syndrome. APMIS. 2011;119:180–6. doi: 10.1111/j.1600-0463.2010.02708.x. [DOI] [PubMed] [Google Scholar]
  • 8.Myllymäki J, Saha H, Mustonen J, Helin H, Pasternack A. IgM nephropathy: clinical picture and long-term prognosis. Am J Kidney Dis. 2003;41: 343. doi: 10.1053/ajkd.2003.50042. [DOI] [PubMed] [Google Scholar]
  • 9.O’Donoghue DJ, Lawler W, Hunt LP, Acheson EJ, Mallick NP. IgM-associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators. Q J Med. 1991;79:333. [PubMed] [Google Scholar]
  • 10.No authors listed. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 1985;27(2):442–9. doi: 10.1038/ki.1985.29. [DOI] [PubMed] [Google Scholar]
  • 11.Singhai AM, Vanikar AV, Goplani KR, Kanodia KV, Patel RD, Suthar KS. et al. Immunoglobulin M nephropathy in adults and adolescents in India: a single center study of natural history. Indian J Pathol Microbiol. 2011;54 (1):3–6. doi: 10.4103/0377-4929.77315. [DOI] [PubMed] [Google Scholar]
  • 12.Tejani A, Nicastri AD. Mesangial IgM nephropathy. Nephron. 1983;35(1):1–5. doi: 10.1159/000183035. [DOI] [PubMed] [Google Scholar]
  • 13.Chan YH, Wong KM, Choi KS, Chak WL, Cheung CY. Clinical manifestation and progression of IgMmesangial nephropathy: a single center perspective. Hong Kong J Nephrol. 2000;2 (1):23–6. [Google Scholar]
  • 14.Van de Putte LB, de la Riviere GB, van Breda Vriesman PJ. Recurrent or persistent hematuria, sign of mesangial immune-complex deposition. N Engl J Med. 1974;290 (21):1165–70. doi: 10.1056/NEJM197405232902104. [DOI] [PubMed] [Google Scholar]
  • 15.Cavalo T, Johnson MP. Immunopathologic study of minimal change glomerular disease with mesangialIgM deposits. Nephron. 1981;27 (6):281–4. doi: 10.1159/000182071. [DOI] [PubMed] [Google Scholar]
  • 16.Disciullo SO, Abeulo JG, Moalli K, Pezzullo JC. Circulating heavy IgM in IgM nephropathy. Clin Exp Immunol. 1988;73 (3):395–400. [PMC free article] [PubMed] [Google Scholar]
  • 17.Helin H, Mustonen J, Pasternack A, Antonen J. IgM associated glomerulonephritis. Nephron. 1982;31 (1):11–6. doi: 10.1159/000182598. [DOI] [PubMed] [Google Scholar]
  • 18.Hsu HC, Chen WY, Lin GJ, Chen L, Kao SL, Huang CC. et al. Clinical and immunopathologic study of mesangialIgM nephropathy: report of 41 cases. Histopathology. 1984;8 (3):435–46. doi: 10.1111/j.1365-2559.1984.tb02355.x. [DOI] [PubMed] [Google Scholar]
  • 19.Ji-Yun Y, Melvin T, Sibley R, Michael AF. No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. Kidney Int. 1984;25 (1):100–6. doi: 10.1038/ki.1984.14. [DOI] [PubMed] [Google Scholar]
  • 20.Vanikar AV, Kanodia KV, Patel RD, Suthar KS, Patel HV, Gumber MR. et al. IgM nephropathy in India: a single centre experience. Indian J Pediatr. 2012;79(8):1025–7. doi: 10.1007/s12098-012-0693-0. [DOI] [PubMed] [Google Scholar]
  • 21.Lin CY, Chen CH, Lee PP. In vitro B-lymphocyte switch disturbance from IgM into IgG in IgM mesangial nephropathy . Pediatr Nephrol. 1989;3:254–8. doi: 10.1007/BF00858525. [DOI] [PubMed] [Google Scholar]
  • 22.Swartz SJ, Eldin KW, Hicks MJ, Feig DI. Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol. 2009;24: 187. doi: 10.1007/s00467-009-1130-0. [DOI] [PubMed] [Google Scholar]
  • 23.[No authors listed]. Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 1983;24(1):87–94. doi: 10.1038/ki.1983.129. [DOI] [PubMed] [Google Scholar]
  • 24.Al Eisa A, Carner JE, Lirenman DS, Magil AB. Childhood IgM nephropathy: comparison with minimal change disease. Nephron. 1996;72 (1):37–43. doi: 10.1159/000188804. [DOI] [PubMed] [Google Scholar]
  • 25.Border WA. Distinguishing minimal change disease from mesangial disorders. Kidney Int. 1988;34 (3):419–24. doi: 10.1038/ki.1988.197. [DOI] [PubMed] [Google Scholar]
  • 26.Mubarak M, Lanewala A, Kazi JI, Akhter F, Sher A, Fayyaz A. et al. Histopathological spectrum of childhood nephrotic syndrome in children in Pakistan. Clin Exp Nephrol. 2009;13 (6):589–93. doi: 10.1007/s10157-009-0216-0. [DOI] [PubMed] [Google Scholar]
  • 27.Donia AF, Sobh MA, Moustafa FE, Bakr MA, Foda MA. Clinical significance and long term evolution of minimal change histopathologic variants and of IgM nephropathy among Egyptians. J Nephrol. 2000;13 (4):275–81. [PubMed] [Google Scholar]
  • 28.Habib R, Girardin E, Gagnadoux MF, Hinglais N, Levy M, Broyer M. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular “immune deposits”. Pediatr Nephrol. 1988;2:402–8. doi: 10.1007/BF00853431. [DOI] [PubMed] [Google Scholar]
  • 29.Hamed RM. Clinical significance and long term evolution of mesangial proliferative IgM nephropathy among Jordanian children. Ann Saudi Med. 2003;23 (5):323–7. doi: 10.5144/0256-4947.2003.323. [DOI] [PubMed] [Google Scholar]
  • 30.Jungthirapanich J, Singkhwa V, Watana D, Futrakul P, Sensirivatana R, Yenrudi S. Significance of tubulointerstitial fibrosis in paediatricIgM nephropathy. Nephrology. 1997;3:509–14. [Google Scholar]
  • 31.Kazi JI, Mubarak M, Mallick S. Clinicopathologic characteristics of IgM nephropathy in pediatric nephrotic population from PakistanLetter to the editor. J Pak Med Assoc. 2010;76:878. [Google Scholar]
  • 32.Pardo V, Riesgo I, Zilleruelo G, Strauss J. The clinical significance of mesangialIgM deposits and mesangialhypercellularity in minimal change nephrotic syndrome. Am J Kidney Dis. 1984;3 (4):264–9. doi: 10.1016/s0272-6386(84)80043-8. [DOI] [PubMed] [Google Scholar]
  • 33.Saha H, Mustonen J, Pasternack A, Helin H. Clinical follow up of 54 patients with IgM nephropathy. Am J Nephrol. 1989;9 (2):124–8. doi: 10.1159/000167950. [DOI] [PubMed] [Google Scholar]
  • 34.Salmon AH, Kamel D, Mathieson PW. Recurrence of IgM nephropathy in a renal allograft. Nephrol Dial Transplant. 2004;19 (10):2650–2. doi: 10.1093/ndt/gfh434. [DOI] [PubMed] [Google Scholar]
  • 35.Zeis PS, Kavazarakis E, Nakopoulou L, Moustaki M, Messaritaki A, Zeis MP. et al. Glomerulopathy with mesangial IgM deposits: long-term follow up of 64 children. Pediatr Int. 2001;43 (3):287–92. doi: 10.1046/j.1442-200x.2001.01396.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Nephropathology are provided here courtesy of Society of Diabetic Nephropathy

RESOURCES